Business Segments Attovia Therapeutics, Inc.
Stocks
ATTO
US04987L1026
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
12:05:03 18/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 23.20 USD | +4.29% |
|
+2.93% | - |
| 16/09 | Attovia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM | |
| 03/09 | Attovia Therapeutics Q2 Net Loss Widens | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Gene Research and Development | ||
Development of Therapeutic Products in The Fields of Immune-Mediated Diseases | - | 13.5L |
Total Assets | 7.67Cr | 17Cr |
CAPEX | -17.72L | -23.13L |
EBT | -3.98Cr | -6.06Cr |
D&A | 3L | 8L |
Operating Income | -4.16Cr | -6.72Cr |
Net Income | -3.98Cr | -6.06Cr |
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
United States of America | - | 13.5L |
Total Assets | 7.67Cr | 17Cr |
D&A | 3L | 8L |
CAPEX | -17.72L | -23.13L |
Net Income | -3.98Cr | -6.06Cr |
EBT | -3.98Cr | -6.06Cr |
Operating Income | -4.16Cr | -6.72Cr |
- Stock Market
- Stocks
- ATTO Stock
- Financials Attovia Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
